Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bridgepoint in conjunction with an investment in FCG
Mandate

Vinge advises Bridgepoint in conjunction with an investment in FCG

January 25, 2018

Vinge has advised Bridgepoint Development Capital in conjunction with the entry into of a partnership in FCG Holding Sverige AB.

FCG Holding Sverige AB is one of the Nordic region’s leading suppliers of specialist services within risk management, compliance, finance and capital management, financial law and corporate governance, with a focus on the financial sector.

The transaction is conditional upon approval by the Swedish Financial Supervisory Authority.

Vinge’s team primarily consisted of partner Daniel Rosvall together with associates Samra Baytar, Michaela Cronemyr, Christina Odengran and Caroline Krassén. Malin Haag and Carolina Sandell provided advice in connection with the notification to, and approval from, the Swedish Financial Supervisory Authority.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025